Application of Siglec-14 agonist in preparation of anti-HIV drugs
Forsythoside B is screened as a Siglec-14 agonist through multi-conformational scoring and molecular docking technology, agonizing Siglec-14 receptors to inhibit HIV-1 replication, solving the problems of resistance and side effects of existing AIDS treatment drugs, and providing a A new anti-HIV drug direction has achieved effective inhibition of HIV-1.
Patent Information
- Application Number
- CN202411279106.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-12
- Publication Date
- 2024-11-08
AI Technical Summary
Existing AIDS treatment drugs have drug resistance, high cost, high toxicity and side effects caused by long-term use, and cannot completely remove viruses in the body, making it difficult to effectively prevent or treat HIV infection.
Multi-conformational scoring and molecular docking technology were used to screen out natural small-molecule compounds targeting Siglec-14 receptors, especially Forsythoside B as Siglec-14 agonist, and promotes their expression to inhibit HIV-1 by agonizing Siglec-14 receptors. Copy of .
Forsythoside B showed concentration-dependent inhibition of HIV-1 replication in in vitro cell experiments, with potential anti-HIV drug utilization value, providing a new direction for HIV drug treatment, reducing viral load and increasing patients Quality of life.
Smart Images

Figure CN118903434A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of research and development of AIDS therapeutic drugs, and specifically relates to the application of Siglec-14 agonist Forsythoside B in the preparation of anti-HIV drugs. Background Art
[0002] Acquired Immune Deficiency Syndrome (AIDS), also known as AIDS, is a chronic infectious disease caused by human immunodeficiency virus (HIV) infection. It has become a global public health issue that seriously affects people's health.
[0003] At present, AIDS patients generally receive combination antiretroviral therapy (cART), which has greatly curbed the spread of AIDS. Although cART greatly inhibits HIV replication, reduces viral load levels, and delays disease progression. However, due to the existence of latent viral reservoirs, existing cART treatments cannot completely eliminate the virus in the body, and HIV can continue to replicate at a low level in the host. In addition, the high mutation and instability of HIV genetic genes make it very easy to produce drug-resistant virus strains during long-term cART treatment. To date, all drugs for the treatment of HIV / AIDS have been reported to be resistant, and long-term use also has problems such as long treatment cycles, high costs, and obvious side effects.
[0004] Chinese patent CN116270590A (publication date: June 23, 2023) discloses the use of K-41A-derived polyether compounds K-41B and K-41Bm in the preparation of anti-HIV drugs. The present invention uses three cell virus infection models, namely TZM-bl-HIV-1IIIB, MT-2-HIV-1IIIB and peripheral blood mononuclear cells (PBMCs)-HIV-1BaL, to verify the anti-HIV activity of the polyether compounds. The present invention is the first to use three cell infection systems to carry out anti-HIV-1 activity studies on polyether compounds K-41B and K-41Bm derived from the marine natural product K-41A in HIV-1 virus strains with different tropisms, and combine multiple experiments to reveal the potential anti-HIV action mechanism of the two, which is original and innovative. In addition, the present invention finds that K-41B and K-41Bm may be potential multi-target inhibitors against HIV-1, and can effectively inhibit the replication of HIV-1IIIB and HIV-1BaL viruses at the same time, have broad-spectrum anti-HIV-1 activity, and can be used to prevent or treat HIV infection, becoming potential anti-HIV drugs.
[0005] Chinese patent CN116077434A (publication date: May 9, 2023) discloses the use of Guiqi Buxue Oral Liquid in the preparation of anti-HIV virus drugs, wherein the HIV virus is HIV-1 virus. The present invention adopts two cell-virus infection models, TZM-bl-HIV-1ⅢB and MT-2-HIV-1ⅢB, to detect the anti-HIV-1 activity of Guiqi Buxue Oral Liquid, and conducts a study on the anti-HIV-1 mechanism of action of Guiqi Buxue Oral Liquid based on network pharmacology. It is found that Guiqi Buxue Oral Liquid can inhibit the replication of HIV-1 in TZM-b1 and MT2 cells in a dose-dependent manner while maintaining good cell activity. The mechanism of action study found that Guiqi Buxue Oral Liquid mainly exerts immune regulation and inflammation inhibition by regulating immune and inflammation-related pathways, thereby inhibiting viral replication, which is of great significance to the redevelopment of the value of the drug.
[0006] In view of the drawbacks of imported anti-AIDS drugs, such as high price, high toxicity, and drug resistance after long-term use, research and development of low-cost and effective natural small molecule compounds are of great significance for the prevention and treatment of AIDS. Clinical practice has shown that natural small molecule compounds can effectively reduce HIV viral load, increase the number of CD4+T cells, and have certain advantages in improving the quality of life of patients, delaying the progression of the disease, and having few adverse reactions. The use of natural small molecule compounds to prevent and treat AIDS is convenient, cheap and effective, and solves the drawbacks of cART therapy, such as high price, high toxicity, and drug resistance after long-term use. It is an important source for screening new anti-HIV-1 drugs.
[0007] Sialic acid-binding immunoglobulin-like lectins (Siglecs) are a class of receptors that recognize sialic acid glycans and are widely expressed on immune cells. They can mediate cell-cell or cell-pathogen interactions by recognizing sugar chain structures containing sialic acid, and play an important regulatory role in immune responses. Currently, research on Siglec-14 is mainly focused on the fields of inflammatory diseases and autoimmune diseases, including myeloid inflammatory responses, bacterial infections such as group B streptococci, and the regulation of inflammatory responses caused by influenza viruses. In RNA virus infections, especially HIV infections, the role of Siglec-14 has not been fully understood.
[0008] In summary, the present invention provides the application of Siglec-14 agonists in anti-HIV and reveals its potential antiviral mechanism. Summary of the invention
[0009] To this end, this application provides the following technical solutions:
[0010] Use of Siglec-14 agonist in the preparation of anti-HIV drugs, wherein the HIV is HIV-1 virus.
[0011] The present invention utilizes multi-conformation scoring and molecular docking technology to screen out natural small molecule compounds targeting Siglec-14 receptors. The docking scores and MM-GBSA binding energy show that Rebaudioside A, Forsythoside B, 9"-Methylsalvianolate B, Polimoside, Verbascoside, Plantamajoside, Acarbose, Manninotriose, Stevioside, Vaccarin, and Oroxin B have strong potential affinity interaction potential with Siglec-14.
[0012] Preferably, Forsythoside B has the strongest potential affinity interaction with Siglec-14.
[0013] Preferably, the Siglec-14 agonist is one or more compositions including Forsythoside B.
[0014] Preferably, the HIV-1 virus strain is HIV-1BaL,
[0015] Preferably, the Forsythoside B is a phenylethanol glycoside compound extracted from Forsythia suspensa, and has pharmacological effects such as antibacterial, anti-inflammatory, antioxidant and neuroprotective.
[0016] Compared with the prior art, the advantages and effects of the present invention are as follows:
[0017] 1. The present invention uses multi-conformation scoring and molecular docking technology to screen out natural small molecule compounds targeting Siglec-14 receptors. The docking score and MM-GBSA binding energy show that there is a strong potential for interaction between Forsythoside B and Siglec-14. Subsequent in vitro cell experiments were used to verify the replication and potential mechanism of action of Forsythoside B against HIV-1. The experimental results showed that Forsythoside B can inhibit the replication of HIV-1 in macrophages in a concentration-dependent manner while maintaining good cell activity. Its mechanism of action is that Forsythoside B stimulates Siglec-14 receptors and promotes their expression, thereby exerting a potential anti-HIV-1 effect.
[0018] 2. Forsythoside B has potential value as an anti-HIV drug. The present invention is of great significance to the redevelopment of the drug value and provides a new direction for HIV drug treatment.
[0019] The above description is only an overview of the technical solution of the present application. In order to more clearly understand the technical means of the present application so that it can be implemented in accordance with the contents of the specification, and to make the above and other purposes, features and advantages of the present application more obvious and easy to understand, the following is a detailed description of the preferred embodiments of the present application in conjunction with the accompanying drawings as follows.
[0020] Based on the detailed description of the specific embodiments of the present application in combination with the accompanying drawings below, those skilled in the art will become more aware of the above and other objects, advantages and features of the present application. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] In order to more clearly illustrate the technical solutions in the embodiments of the present application or the prior art, the drawings required for use in the embodiments or the prior art descriptions are briefly introduced below. Obviously, the drawings described below are some embodiments of the present application. For ordinary technicians in this field, other drawings can also be obtained based on these drawings without creative work. In all drawings, similar elements or parts are generally identified by similar reference numerals. In the drawings, each element or part is not necessarily drawn according to the actual scale.
[0022] in:
[0023] Figure 1 Ramachandran diagram of the Siglec-14 homology model;
[0024] Figure 2 This is the Verify_3D analysis result diagram of Siglec-14 homology model;
[0025] Figure 3 Figure 2. AlphaFol2 modeling results for evaluating Siglec-14 using pLDDT scores.
[0026] Figure 4 Protein superposition and alignment diagrams for homology modeling and AlphaFol2 modeling;
[0027] Figure 5 This is the docking coordinate region diagram of Siglec-14 amino acid residues;
[0028] Figure 6 This is the molecular docking diagram of Siglec-14 and Forsythoside B;
[0029] Figure 7 Schematic diagram of the effect of Forsythoside B on THP-1 derived macrophage survival rate, HIV-1 replication and induced Siglec-14 expression;
[0030] Figure 8Schematic diagram of Forsythoside B inhibiting HIV-1 replication in Siglec-14 knockdown macrophages and control cells;
[0031] Fig. 9 Schematic diagram of Forsythoside B regulating the inflammatory response and antiviral effect of Siglec-14 knockdown macrophages after HIV infection.
[0032] Fig.10 Intersection target screening and analysis diagram for RNA-seq sequencing of Forsythoside B and Siglec-14 knockdown cells infected with HIV-BaL;
[0033] Fig.11 Schematic diagram of the effect of Forsythoside B on the expression levels of JAK1, STAT1 and STAT2 in Siglec-14 knockdown cells. DETAILED DESCRIPTION
[0034] To make the purpose, technical scheme and advantages of the embodiment of the present application clearer, the technical scheme in the embodiment of the present application will be clearly and completely described below in conjunction with the accompanying drawings in the embodiment of the present application. Obviously, the described embodiment is a part of the embodiment of the present application, rather than all of the embodiments. In the following description, specific details such as specific configuration and components are provided only to help fully understand the embodiments of the present application. Therefore, it should be clear to those skilled in the art that various changes and modifications can be made to the embodiments described herein without departing from the scope and spirit of the present application. In addition, for clarity and brevity, the description of known functions and structures is omitted in the embodiment.
[0035] It should be understood that the references to "one embodiment" or "this embodiment" throughout the specification mean that the specific features, structures, or characteristics associated with the embodiment are included in at least one embodiment of the present application. Therefore, the references to "one embodiment" or "this embodiment" appearing throughout the specification do not necessarily refer to the same embodiment. In addition, these specific features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
[0036] In addition, the present application may repeat reference numerals and / or letters in different examples. This repetition is for the purpose of simplicity and clarity, and does not in itself indicate the relationship between the various embodiments and / or settings discussed.
[0037] The term "and / or" in this article is only a description of the association relationship of associated objects, indicating that there can be three relationships. For example, A and / or B can mean: A exists alone, B exists alone, and A and B exist at the same time. The term " / and" in this article describes another type of association object relationship, indicating that there can be two relationships. For example, A / and B can mean: A exists alone, and A and B exist alone. In addition, the character " / " in this article generally indicates that the previous and next associated objects are in an "or" relationship.
[0038] The term "at least one" in this article is merely a description of the association relationship of associated objects, indicating that there may be three relationships. For example, at least one of A and B can mean: A exists alone, A and B exist at the same time, and B exists alone.
[0039] It should also be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprises" or any other variations thereof are intended to cover non-exclusive inclusions.
[0040] Terms and Definitions
[0041] As used herein and in the accompanying drawings, “Forsythoside B” is the same as “FTS·B”, i.e. Forsythoside B.
[0042] Example 1
[0043] This example is a process of predicting the structure of Siglec-14 protein by homology modeling and Alphafold2 modeling.
[0044] Please refer to Figure 1-4 In this example, homology modeling and Alphafold2 modeling were performed on the Siglec-14 protein based on its amino acid sequence. Figure 1 , homology modeling results show that the Siglec-14 protein structure has 91.12%, 4.82% and 1.73% percentages in the Ramachandran favorable region, Ramachandran outlier point and Rotamer outlier point, respectively. Please refer to Figure 2 , the alignment of the Siglec-14 model to its amino acid sequence was evaluated using Verify3D, with a PROVE score of 69.70%. Please refer to Figure 3 , the Alphafold2 modeling results of Siglec-14 were evaluated and the pLDDT score obtained reached the optimized value of 82.897. This high pLDDT score reflects the overall quality and reliability of the model structure. Please refer to Figure 4 , protein superposition and alignment are performed in the homology model, the homology model is represented in orange and the Alphafold2 model is represented in cyan.
[0045] Example 2
[0046] This example is a process of molecular dynamics simulation to identify the docking coordinate region of Siglec-14 amino acid residues.
[0047] Please refer to Figure 5 In this example, the lowest free energy-related conformation of Siglec-14 was investigated by molecular dynamics (MD) simulation for 100 ns. Figure 5 ab, In the 100ns MD simulation, we conducted a detailed analysis of the conformation of Siglec-14 in the lowest free energy state, and the free energy 2D and 3D scenes drawn based on the root mean square deviation (RMSD) and the radius of rotation (Rg) revealed the characteristics of the protein's energy-favorable state. Among them, the blue area corresponds to the lower energy state, and the red area represents the higher energy state. Please refer to Figure 5 c, five representative conformations are further extracted from the MD simulation, which are obtained from the low energy state at a specific time point. By quickly superimposing and comparing the conformations captured at 22ns, 34ns, 46ns, 58ns and 76ns, the results reveal the dynamic characteristics of the protein structure and highlight the changes that occur during the simulation. Please refer to Figure 5 d, Alanine scanning identified amino acid residues 54-61 as a critical region. Figure 5 ef, when the amino acid residues 54-61 in the key region were mutated to alanine, the free energy fluctuation increased significantly, indicating that these residues play a vital role in maintaining the stability and function of Siglec-14. At the same time, this further proves the rationality of this region as a docking coordinate for screening natural small molecule compounds.
[0048] Example 3
[0049] This embodiment is a process of screening natural small molecule compounds targeting Siglec-14 using multi-conformation scoring and molecular docking technology.
[0050] This example combines molecular docking and multi-conformational virtual screening technology to screen out 9860 natural small molecule compounds that may target Siglec-14 receptors from the Traditional Chinese Medicine and Natural Product libraries databases. Through docking scores, binding free energy (MM / GBSA), target binding mode (with or without π-π interaction force, cation-π interaction force) and other parameters, this example evaluates the feasibility of these natural small molecule compounds as potential drugs targeting Siglec-14. Table 1 lists the top 10 natural small molecule compounds with strong docking affinity to the Siglec-14 receptor.
[0051] Use of Siglec-14 agonist in the preparation of anti-HIV drugs, wherein the HIV is HIV-1 virus.
[0052] The present invention utilizes multi-conformation scoring and molecular docking technology to screen out natural small molecule compounds targeting Siglec-14 receptors. The docking scores and MM-GBSA binding energy show that Rebaudioside A, Forsythoside B, 9"-Methylsalvianolate B, Polimoside, Verbascoside, Plantamajoside, Acarbose, Manninotriose, Stevioside, Vaccarin, and Oroxin B have strong potential affinity interaction potential with Siglec-14.
[0053] Preferably, Forsythoside B has the strongest potential affinity interaction with Siglec-14.
[0054] Table 1 Candidate natural small molecule compounds with high multi-conformation scores for Siglec-14
[0055]
[0056] The results in Table 1 show that the docking of Forsythoside B with multiple conformations of Siglec-14 shows good prospects. The docking score (-12.202) and MM-GBSA binding energy (-81.65 Kcal / mol) indicate that there may be a strong interaction potential between the two. Therefore, in order to clarify the binding characteristics of Forsythoside B and Siglec14, this example analyzes the binding sites and interaction modes of the two by molecular docking. Please refer to Figure 6a, Forsythoside B and Siglec-14 targeting site, 3D binding site is shown in cartoon form, the compound is shown in stick form, the figure reveals the interaction between Forsythoside B and Siglec-14 specific region. Please refer to Figure 6 b, is the direct interaction force between Forsythoside B and Siglec-14. This result further visualizes and marks the interaction force between Forsythoside B and Siglec-14, including hydrogen bonds and hydrophobic interactions. When the Siglec-14 amino acid residues are GLY94, ASP95, TYR57, THR75 and PRO54, they can form hydrogen bonds with Forsythoside B. At the same time, Forsythoside B also has hydrophobic interactions with Siglec-14 residues PRO78, PRO55 and PRO54, which further enhances the binding stability between the two. These molecular-level findings not only deepen our understanding of the interaction between Forsythoside B and Siglec-14 receptors, but also provide reference significance for the subsequent design and optimization of drugs targeting Siglec-14.
[0057] Example 4
[0058] The present invention first analyzes whether Forsythoside B affects HIV-1 replication in THP-1-derived macrophages, and then verifies the common effects of Forsythoside B and Siglec-14 on HIV-1 replication in Siglec-14 knockdown macrophages.
[0059] Please refer to Figure 7 In this study, Forsythoside B was tested for cell activity in THP-1 cells, and the effects of Forsythoside B on HIV-1 replication and Siglec-14 expression were further analyzed. The Forsythoside B used in the experiment was provided by Chengdu Munster Biotechnology Co., Ltd., and the THP-1 cells and HIV-1BaL virus strain used in the experiment were owned by the laboratory.
[0060] (1) Determine the effect of Forsythoside B on the survival rate of THP-1 derived macrophages.
[0061] Figure 7a is the effect of Forsythoside B on the activity of THP-1 derived macrophages. Compared with the control group (DMSO), Forsythoside B at concentrations of 6.25, 12.5, 25, and 50uM can promote the proliferation of THP-1 derived macrophages, and the enhancement effect is concentration-dependent, while Forsythoside B at a concentration of 100uM begins to inhibit cell activity. Therefore, the subsequent experiments used the four concentrations of 6.25, 12.5, 25, and 50uM.
[0062] In order to explore whether Forsythoside B has an anti-HIV-1 infection effect, the present invention added different concentrations of Forsythoside B to THP-1-derived macrophages infected with HIV-1BaL virus strain, and detected changes in HIV-1-BaL-TLR mRNA and HIV-1p24 protein content in the supernatant.
[0063] Figure 7 bc Forsythoside B reduces HIV-1-BaL-LTR mRNA and HIV-1p24 protein levels in THP-1 derived macrophages. The results showed that the levels of HIV-1-BaL-LTR mRNA and HIV-1p24 protein in the Forsythoside B-added group decreased significantly in a concentration-dependent manner.
[0064] The results suggest that Forsythoside B can inhibit the replication of HIV-1 in THP-1-derived macrophages and exert an anti-HIV-1 effect.
[0065] (2) To determine whether Forsythoside B is an agonist of Siglec-14 and whether it affects the expression levels of Siglec-14 mRNA and protein.
[0066] Different concentrations of Forsythoside B were added to THP-1 derived macrophages to detect the expression of Siglec-14 at the transcriptional and translational levels. Figure 7 de is that Forsythoside B promotes the expression of Siglec-14 in THP-1 derived macrophages at the transcriptional and translational levels. The results showed that the mRNA and protein levels of Siglec-14 in the Forsythoside B-treated group were higher than those in the control group, suggesting that Forsythoside B may act as a Siglec-14 agonist and promote Siglec-14 expression at the transcriptional and translational levels.
[0067] Example 5
[0068] Based on Example 4, please refer to Figure 8In this example, we verified whether Forsythoside B exerts its anti-HIV-1 effect by promoting Siglec-14 expression in Siglec-14 knockdown macrophages.
[0069] This example detects the effects of the above four concentrations of Forsythoside B on the activity of Siglec-14 knockdown macrophages and control cells. Figure 8 ab are the effects of Forsythoside B on the activity of Siglec-14 knockdown macrophages and control cells. The results showed that these four concentrations of Forsythoside B can promote the proliferation of Siglec-14 knockdown macrophages and control cells.
[0070] Then, HIV-1BaL virus strain was used to infect Siglec-14 knockdown macrophages and control cells, and different concentrations of Forsythoside B were added 12 hours after infection. Cell culture supernatant was collected 48 hours later, and HIV-1p24 protein content was detected by ELISA. Figure 8 ce is that Forsythoside B reduces HIV-1p24 protein levels in Siglec-14 knockdown cells and control cells. The results showed that as the concentration of Forsythoside B increased, the difference in HIV-1p24 protein levels between the two groups of cells gradually narrowed; when the concentration of Forsythoside B was 25uM and 50uM, the HIV-1p24 protein levels of the two groups of cells tended to be consistent, which showed that Forsythoside B may reduce the trend of increased HIV-1p24 protein levels caused by Siglec-14 knockdown macrophages; when the HIV-1p24 protein levels of the two groups of cells were compared separately, the HIV-1p24 protein level of Siglec-14 knockdown macrophages decreased in a concentration-dependent manner, further indicating that Forsythoside B may inhibit HIV-1 replication by promoting the expression of Siglec-14.
[0071] Example 6
[0072] Previous studies by the research group have shown that Siglec-14 has a regulatory effect on the immune response to HIV-1 infection in macrophages. Specifically, Siglec-14 may exert its anti-HIV-1 effect by inhibiting the secretion of pro-inflammatory factors and promoting the secretion of antiviral effector factors ISGs and chemokines. In addition, Forsythoside B has been shown to inhibit the expression of TNF-α, IL-6 and IκB, regulate the NF-κB signaling pathway and exert anti-inflammatory effects. Please refer to Fig. 9This example is based on the previous results of the research group and literature research, and explores the effect of adding different concentrations of Forsythoside B on the mRNA expression levels of inflammatory factors, antiviral factors and chemokines after HIV-BaL infection of Siglec-14 knockdown macrophages.
[0073] Fig. 9 ab is the regulatory effect of Forsythoside B on proinflammatory factors after Siglec-14 knockdown macrophages were infected with HIV-1BaL. The results showed that after HIV infection, compared with the control group (DMSO), the Forsythoside B-added group inhibited the mRNA secretion of proinflammatory factors IL-6, TNF-α, IL-1β and IL-18 in Siglec-14 knockdown macrophages, and the inhibitory effect was concentration-dependent.
[0074] Macrophages are key hosts for HIV-1 infection and play a key role in the innate immune response by producing type I interferon (IFN-I) and inducing interferon-stimulated genes (ISGs). Therefore, maintaining a balance between the IFN signaling pathway and the ISGs response is essential for effective defense against HIV-1 infection. Our previous studies also showed that the expression levels of antiviral-related factors ISG56, ISG54, and ISG60 mRNA were downregulated after Siglec-14 knockdown macrophages were infected with HIV-1BaL. Based on this, this application detected the mRNA expression levels of the two antiviral factors ISG56 and ISG58. Fig. 9 c is the regulatory effect of Forsythoside B on interferon-stimulated factors after Siglec-14 knockdown macrophages were infected with HIV. The results showed that compared with the HIV-BaL control group (DMSO), the mRNA expression levels of ISG56 and ISG58 in Siglec-14 knockdown macrophages were significantly upregulated after Forsythoside B treatment, and the difference was statistically significant, suggesting that Forsythoside B can upregulate the expression of antiviral effector factors ISGs in Siglec-14 knockdown macrophages and play an anti-HIV-1 role.
[0075] As an important antigen presenting cell, macrophages also secrete a variety of chemokines, which activate specific immune cell functions by attracting and aggregating more immune cells, participate in immune response and maintain tissue homeostasis, and play a key role in macrophage immune function and immune regulation. Therefore, in order to explore the immune response of Forsythoside B to HIV infection after Siglec-14 knockdown macrophages infected with HIV-1BaL, this application also detected the expression of two chemokines, CXCL10 and MIP-1. Fig. 9d is the effect of Forsythoside B on the mRNA expression changes of chemokines after Siglec-14 knockdown macrophages were infected with HIV. The results showed that after Forsythoside B treatment, these two factors had significant differences in the Siglec-14 knockdown macrophage infection group and the infection control group (DMSO), similar to the changes in the above-mentioned ISGs, both showing an upregulation of expression levels. This result further suggests that Forsythoside B may exert its potential anti-HIV-1 effect by regulating the expression of immune factors in Siglec-14 knockdown macrophages.
[0076] Example 7
[0077] In this example, a PPI network, GO and KEGG enrichment analysis were constructed based on RNA-seq sequencing of Siglec-14 knockdown macrophages infected with HIV-BaL virus strain and potential targets of Forsythoside B.
[0078] The present application performed transcriptome sequencing on HIV-1BaL infected Siglec-14 knockdown macrophages and control cells. The analysis identified a total of 1757 differentially expressed genes. Through screening of SwissTargetPrediction, PharmMapper and ComparativeToxicogenomics databases, the present application identified 212 genes associated with Forsythoside B. Fig.10 a is a Venn diagram of differentially expressed genes in Siglec-14 knockdown macrophages infected with HIV-1BaL and potential targets of Forsythoside B. The results showed that there were 19 overlapping target genes.
[0079] Therefore, this application constructed a PPI network consisting of 15 nodes and 27 edges based on these 19 overlapping genes and visualized the degree values using Cytoscape software. Fig.10 bc, is the PPI network diagram and key targets of Siglec-14 knockdown cells and Forsythoside B intersection targets. The results showed that signal transducer and activator of transcription 1 (STAT1), annexin A5 (ANXA5), CC motif chemokine ligand 5 (CCL5), matrix metallopeptidase 13 (MMP13) and urokinase plasminogen activator (PLAU) may be the key factors involved in the anti-HIV-1 replication mechanism of Forsythoside B and Siglec-14.
[0080] Based on the PPI network analysis, this application further identified key factors that may be involved in the anti-HIV-1 replication mechanism. In order to further explore the biological significance of these genes, this example performed GO and KEGG pathway enrichment analysis on these cross-targets, and the screening condition was set to p<0.05. GO analysis generated 85 entries, which were divided into biological processes (BP, n=70), cellular components (CC, n=6), and molecular functions (MF, n=9). Please refer to Fig.10 de, is a bubble chart of GO function and KEGG enrichment analysis. This example shows the top 10 BP items, including cell proliferation regulation, external stimulus response regulation, fibrinolysis regulation, etc. MF is composed of serine endopeptidase activity, protease binding, CCR5 chemokine receptor binding, etc. CC mainly includes extracellular matrix, focal adhesion, cell surface, etc. KEGG enrichment analysis generated 41 entries, and this example identified the top 20 KEGG signaling pathways based on p-values. Among them, the enriched antiviral pathways mainly include Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, chemokine signaling pathway, etc. These signaling pathways may be the key pathways mediating the anti-HIV-1 effects of Forsythoside B and Siglec-14.
[0081] Example 8
[0082] This study was conducted to verify the effect of Forsythoside B on the expression of JAK1 / STAT1 signaling pathway-related factors in Siglec-14 knockdown macrophages.
[0083] Example 7 identified STAT1 as a potential target of Siglec-14 knockdown macrophages and Forsythoside B with the highest degree score, indicating that it may play a core role in the regulatory network ( Fig.10 c). STAT1 is considered to be a key regulator in the Toll-like receptor signaling pathway and is essential for viral recognition and immune response. IFN induces the expression of ISGs and IFN-related factors by activating the Janus kinase signal transducer and activator (JAK1 / STAT1) pathway, which is a key pathway for antiviral infection. This example assumes that Forsythoside B exerts its antiviral effect in Siglec-14 knockdown macrophages by targeting the JAK1 / STAT1 signaling pathway. To verify this hypothesis, this example analyzed the expression of key JAK1 / STAT1 signaling pathway factors in Siglec-14 knockdown macrophages infected with the HIV-1BaL virus strain treated with Forsythoside B. Please refer to Fig.11a, after infection with HIV-1BaL virus strain, the mRNA expression of JAK1, STAT1 and STAT2 in Siglec-14 knockdown macrophages treated with Forsythoside B. The results showed that compared with the infection control group (DMSO), Forsythoside B treatment significantly increased the mRNA expression levels of these genes. Please refer to Fig.11 b, Forsythoside B changes the protein levels of JAK1, STAT1, and STAT2 in Siglec-14 knockdown macrophages after infection with HIV-1BaL. Western Blot results showed that these proteins were upregulated after Forsythoside B treatment, and the trend of change was consistent with the change of mRNA. These findings suggest that Forsythoside B may regulate the JAK1 / STAT1 signaling pathway by promoting the expression of Siglec-14, which is important for controlling HIV-1 replication and reducing the inflammatory response associated with viral replication. This discovery not only provides a new perspective for our understanding of the antiviral mechanism of Forsythoside B, but also provides a potential molecular target for the development of new anti-HIV-1 therapeutic strategies.
[0084] In summary, the present invention uses multi-conformation scoring and molecular selection for the first time to select multiple compounds, and demonstrates that Forsythoside B can target Siglec-14 receptors. The present invention further conducts in vitro cell experiments of Forsythoside B against HIV-1 in THP-1 cell lines, Siglec-14 knockdown macrophages and control cells, and combines qPCR, ELISA, Western Blot and other experiments to verify that Forsythoside B acts as an agonist of Siglec-14, promotes its expression on macrophages, and exerts a potential anti-HIV-1 effect through the JAK1 / STAT1 signaling pathway. The invention is original and innovative.
[0085] The specific implementation methods described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific implementation method of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.
Claims
1. The use of Siglec-14 agonist in the preparation of anti-HIV drugs, characterized in that: The HIV virus is HIV-1 virus.
2. Use of the Siglec-14 agonist according to claim 1 in the preparation of anti-HIV drugs, characterized in that: The natural small molecule compounds targeting Siglec-14 receptors include one or more combinations of Rebaudioside A, Forsythoside B, 9"-Methylsalvianolate B, Polimoside, Verbascoside, Plantamajoside, Acarbose, Manninotriose, Stevioside, Vaccarin and Oroxin B.
3. Use of the Siglec-14 agonist according to claim 2 in the preparation of anti-HIV drugs, characterized in that: The Siglec-14 agonist is one or more compositions including Forsythoside B.
